Frede Donskov

List of Publications by Year
in descending order

230 papers	21,897 citations	29994 54 h-index	9311 143 g-index
235 all docs	235 docs citations	235 times ranked	18033 citing authors

#	Article	IF	Citations
1	First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. European Urology, 2022, 81, 266-271.	0.9	33
2	Impact of comorbidity on renal cell carcinoma prognosis: a nationwide cohort study. Acta OncolÃ³gica, 2022, 61, 58-63.	0.8	6
3	Outcome and prognosis after adrenal metastasectomy: nationwide study. BJS Open, 2022, 6, .	0.7	6
4	First-line therapy for metastatic renal cell carcinoma with pancreatic metastases: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology, 2022, 40, 317-317.	0.8	2
5	Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2022, 40, 308-308.	0.8	2
6	Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. JAMA Oncology, 2022, 8, 275.	3.4	75
7	Predictors of objective response to first-line immuno-oncology combination therapies in metastatic renal cell carcinoma: Results from the international metastatic renal cell database consortium (IMDC).. Journal of Clinical Oncology, 2022, 40, 310-310.	0.8	1
8	Prognostic Utility of Parameters Derived From Pretreatment Dual-Layer Spectral-Detector CT in Patients With Metastatic Renal Cell Carcinoma. American Journal of Roentgenology, 2022, 218, 867-876.	1.0	6
9	GRade, Age, Nodes, and Tumor (GRANT) compared with Leibovich score to predict survival in localized renal cell carcinoma: A nationwide study. International Journal of Urology, 2022, 29, 641-645.	0.5	4
10	Conditional survival and longâ€term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer, 2022, 128, 2085-2097.	2.0	103
11	Early reduction in spectral dual-layer detector CT parameters as favorable imaging biomarkers in patients with metastatic renal cell carcinoma. European Radiology, 2022, 32, 7323-7334.	2.3	5
12	Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open, 2022, 5, e2216379.	2.8	10
13	Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy. European Journal of Cancer, 2022, 171, 124-132.	1.3	14
14	von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance. European Journal of Medical Genetics, 2022, 65, 104538.	0.7	23
15	Prognostic value of the lung immune prognostic index in patients with untreated advanced renal cell carcinoma (aRCC) receiving nivolumab plus ipilimumab (N+I) or sunitinib (SUN) in the CheckMate 214 trial.. Journal of Clinical Oncology, 2022, 40, 4538-4538.	0.8	1
16	Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. European Urology, 2021, 79, 659-662.	0.9	64
17	Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 78-86.	3.2	154
18	Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. European Urology Oncology, 2021, 4, 102-111.	2.6	26

#	Article	IF	Citations
19	Renal cell carcinoma with non-clear cell histology or sarcomatoid differentiation: recent insight in an unmet clinical need. Annals of Translational Medicine, 2021, 9, 97-97.	0.7	3
20	Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. JAMA Network Open, 2021, 4, e2021869.	2.8	104
21	Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. European Urology, 2021, 79, 334-338.	0.9	39
22	Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Nonâ€“Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 2021, 39, 1029-1039.	0.8	145
23	Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 2021, 39, 1020-1028.	0.8	83
24	Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinib. BJU International, 2021, 128, 254-261.	1.3	1
25	Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology, 2021, 39, 4554-4554.	0.8	1
26	First-line therapy in patients with metastatic renal cell carcinoma (mRCC): Results from consecutive patients over 25 years in a single institution.. Journal of Clinical Oncology, 2021, 39, e16574-e16574.	0.8	0
27	Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma. JAMA Oncology, 2021, 7, 773.	3.4	21
28	Outcomes based on age in patients with metastatic renal cell carcinoma treated with first line targeted therapy or checkpoint immunotherapy: Older patients more prone to toxicity. Journal of Geriatric Oncology, 2021, 12, 827-833.	0.5	14
29	Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) â€“ an International mRCC Database Consortium (IMDC) analysis. Journal of Geriatric Oncology, 2021, 12, 820-826.	0.5	10
30	Abstract CT188: IMmotion151: updated overall survival (OS) and exploratory analysis of the association of gene expression and clinical outcomes with atezolizumab plus bevacizumab vs sunitinib in patients with locally advanced or metastatic renal cell carcinoma (mRCC). Cancer Research, 2021, 81, CT188-CT188.	0.4	3
31	Prognostic value of DCE-CT-derived blood volume and flow compared to core biopsy microvessel density in patients with metastatic renal cell carcinoma. European Radiology Experimental, 2021, 5, 32.	1.7	2
32	Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. European Journal of Cancer, 2021, 151, 115-125.	1.3	22
33	Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study. Clinical Genitourinary Cancer, 2021, 19, 354-361.	0.9	5
34	Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases. Cardio-Oncology, 2021, 7, 27.	0.8	17
35	661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). Annals of Oncology, 2021, 32, S685-S687.	0.6	29
36	666P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC): Results after a minimum of 41 months of follow-up from KEYNOTE-427 cohort A. Annals of Oncology, 2021, 32, S691-S692.	0.6	0

#	Article	IF	Citations
37	Treatment and Survival in Advanced Non-Small Cell Lung Cancer, Urothelial, Ovarian, Gastric and Kidney Cancer: A Nationwide Comprehensive Evaluation. Clinical Epidemiology, 2021, Volume 13, 871-882.	1.5	1
38	662P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced nonâ€“clear cell renal cell carcinoma (nccRCC): Results after a minimum of 34 months of follow-up from KEYNOTE-427 cohort B. Annals of Oncology, 2021, 32, S687.	0.6	0
39	Cabozantinib realâ€world effectiveness in the firstâ€through fourthâ€line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer Medicine, 2021, 10, 1212-1221.	1.3	22
40	Blood Volume as a new functional image-based biomarker of progression inÂmetastatic renal cell carcinoma. Scientific Reports, 2021, 11, 19659.	1.6	0
41	Belzutifan for Renal Cell Carcinoma in von Hippelâ€“Lindau Disease. New England Journal of Medicine, 2021, 385, 2036-2046.	13.9	274
42	Pazopanib-Induced Liver Toxicity in Patients With Metastatic Renal Cell Carcinoma: Effect of UGT1A1 Polymorphism on Pazopanib Dose Reduction, Safety, and Patient Outcomes. Clinical Genitourinary Cancer, 2020, 18, 62-68.e2.	0.9	15
43	Elevated neutrophil-lymphocyte ratio combined with hyponatremia indicate poor prognosis in renal cell carcinoma. Acta OncolÃ³gica, 2020, 59, 13-19.	0.8	4
44	Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma. Kidney Cancer, 2020, 4, 29-39.	0.2	2
45	Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. European Journal of Cancer, 2020, 126, 1-10.	1.3	19
46	Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, e350-e359.	0.9	3
47	Baseline blood volume identified by dynamic contrast-enhanced computed tomography as a new independent prognostic factor in metastatic renal cell carcinoma. Translational Oncology, 2020, 13, 100829.	1.7	6
48	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. , 2020, 8, e000891.		160
49	Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with longâ€term followâ€up of the randomized, openâ€label, phase 3 CheckMate 025 trial. Cancer, 2020, 126, 4156-4167.	2.0	201
50	Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open, 2020, 5, e001079.	2.0	343
51	Blood natural killer cells during treatment in recurrent ovarian cancer. Acta OncolÃ³gica, 2020, 59, 1365-1373.	0.8	7
52	18F-FDG Uptake in a Mesonephric Carcinoma. Clinical Nuclear Medicine, 2020, 45, 696-699.	0.7	0
53	711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy. Annals of Oncology, 2020, 31, S559-S560.	0.6	21
54	<p>Registrations of Patients with Renal Cell Carcinoma in the Nationwide Danish Renal Cancer Database versus the Danish Cancer Registry: Data Quality, Completeness and Survival (DaRenCa) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.5	1

#	Article	IF	Citations
55	425P The impact of obesity on treatment outcomes in patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents. Annals of Oncology, 2020, 31, S1408.	0.6	0
56	Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy. Journal of Ovarian Research, 2020, 13, 59.	1.3	13
57	Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts. JCO Global Oncology, 2020, 6, 293-306.	0.8	4
58	Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcomeâ€"Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology, 2020, 3, 530-539.	2.6	29
59	Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group. Oncologist, 2020, 25, 422-430.	1.9	12
60	Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma. Acta OncolÃ³gica, 2020, 59, 652-659.	0.8	28
61	Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. European Urology, 2020, 78, 615-623.	0.9	44
62	Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-NaÃ¯ve Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2020, 26, 2506-2514.	3.2	20
63	Phase II study of the oral HIF-2Î± inhibitor MK-6482 for Von Hippel-Lindau diseaseâ€"associated renal cell carcinoma.. Journal of Clinical Oncology, 2020, 38, 5003-5003.	0.8	40
64	Association of gene expression with clinical outcomes in patients with renal cell carcinoma treated with pembrolizumab in KEYNOTE-427.. Journal of Clinical Oncology, 2020, 38, 5024-5024.	0.8	9
65	First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B.. Journal of Clinical Oncology, 2020, 38, 5034-5034.	0.8	6
66	Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.. Journal of Clinical Oncology, 2020, 38, 5063-5063.	0.8	5
67	Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC): An international mRCC database consortium (IMDC) analysis.. Journal of Clinical Oncology, 2020, 38, 5068-5068.	0.8	2
68	First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A.. Journal of Clinical Oncology, 2020, 38, 5069-5069.	0.8	6
69	Characterizing sites of metastatic involvement in metastatic clear-cell, papillary, and chromophobe renal cell carcinoma.. Journal of Clinical Oncology, 2020, 38, 5071-5071.	0.8	2
70	Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): A propensity score-based analysis.. Journal of Clinical Oncology, 2020, 38, 608-608.	0.8	15
71	Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2020, 38, 609-609.	0.8	51
72	Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2020, 38, 617-617.	0.8	24

#	Article	IF	Citations
73	Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology, 2020, 38, 639-639.	0.8	3
74	Outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first-line Immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials.. Journal of Clinical Oncology, 2020, 38, 5070-5070.	0.8	0
75	Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology, 2020, 38, 642-642.	0.8	9
76	Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology, 2020, 38, 684-684.	0.8	5
77	Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS).. Journal of Clinical Oncology, 2020, 38, 701-701.	0.8	0
78	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 1370-1385.	5.1	594
79	First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A. Annals of Oncology, 2019, 30, v381-v382.	0.6	8
80	Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in advanced renal cell carcinoma (RCC). Annals of Oncology, 2019, 30, v396.	0.6	4
81	First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. European Urology, 2019, 76, 861-867.	0.9	71
82	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet, The, 2019, 393, 2404-2415.	6.3	778
83	Folic Acid Reduces Mucositis in Metastatic Renal Cell Carcinoma Patients: A Retrospective Study. Clinical Genitourinary Cancer, 2019, 17, 254-259.	0.9	4
84	Real-World Outcomes of Nivolumab and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Current Oncology, 2019, 26, 175-179.	0.9	23
85	59â€...Natural killer cells and treatment effect in recurrent ovarian cancer. , 2019, , .		0
86	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology, 2019, 2, 643-648.	2.6	31
87	Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies. Clinical Genitourinary Cancer, 2019, 17, 65-71.	0.9	9
88	Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis. Clinical Cancer Research, 2019, 25, 1165-1173.	3.2	23
89	Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature. Clinical Genitourinary Cancer, 2019, 17, e32-e37.	0.9	18
90	Tissue immune response in epithelial ovarian carcinoma.. Journal of Clinical Oncology, 2019, 37, 2625-2625.	0.8	1

#	Article	IF	Citations
91	Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis.. Journal of Clinical Oncology, 2019, 37, 4512-4512.	0.8	30
92	CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.. Journal of Clinical Oncology, 2019, 37, 4513-4513.	0.8	61
93	KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced nonâ€'clear cell renal cell carcinoma (NCC-RCC).. Journal of Clinical Oncology, 2019, 37, 4569-4569.	0.8	23
94	First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A.. Journal of Clinical Oncology, 2019, 37, 4570-4570.	0.8	14
95	First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.. Journal of Clinical Oncology, 2019, 37, 546-546.	0.8	42
96	Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.. Journal of Clinical Oncology, 2019, 37, 564-564.	0.8	10
97	Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.. Journal of Clinical Oncology, 2019, 37, 581-581.	0.8	14
98	First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology, 2019, 37, 584-584.	0.8	4
99	Real-world assessment of clinical outcomes among first-line (1L) sunitinib (SUN) patients (pts) with metastatic renal cell carcinoma (mRCC) by the international mRCC database consortium (IMDC) risk group.. Journal of Clinical Oncology, 2019, 37, 610-610.	0.8	1
100	Deferred cytoreductive nephrectomy among patients with newly diagnosed metastatic renal cell carcinoma treated initially with sunitinib.. Journal of Clinical Oncology, 2019, 37, 4578-4578.	0.8	0
101	First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC).. Journal of Clinical Oncology, 2019, 37, 4577-4577.	0.8	1
102	A randomized phase II trial of interleukin-2 and interferon-Î± plus bevacizumab versus interleukin-2 and interferon-Î± in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1. Acta OncolÃ³gica, 2018, 57, 589-594.	0.8	19
103	Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma. Clinical Cancer Research, 2018, 24, 3005-3013.	3.2	48
104	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2018, 378, 1277-1290.	13.9	3,334
105	Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. European Urology, 2018, 73, 62-68.	0.9	164
106	Diagnosis of hyponatremia and increased risk of a subsequent cancer diagnosis: results from a nationwide population-based cohort study. Acta OncolÃ³gica, 2018, 57, 522-527.	0.8	9
107	Use of patient outcome endpoints to identify the best functional CT imaging parameters in metastatic renal cell carcinoma patients. British Journal of Radiology, 2018, 91, 20160795.	1.0	10
108	Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. Journal of Clinical Oncology, 2018, 36, 757-764.	0.8	43

#	Article	IF	Citations
109	Clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin inhibitors (mTORI) after immuno-oncology (IO) checkpoint inhibitors. Annals of Oncology, 2018, 29, viii315.	0.6	3
110	Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis. Annals of Oncology, 2018, 29, viii309.	0.6	12
111	Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151. Annals of Oncology, 2018, 29, viii308.	0.6	3
112	Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial. Annals of Oncology, 2018, 29, 2098-2104.	0.6	36
113	Living with Advanced Kidney Cancer and Treatment with Cabozantinib: Through the Eyes of the Patient and the Physician. Oncology and Therapy, 2018, 6, 1-7.	1.0	2
114	Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)1. Kidney Cancer, 2018, 2, 31-36.	0.2	10
115	Hyponatremia associates with poor outcome in metastatic renal cell carcinoma patients treated with everolimus: prognostic impact. Acta OncolÃ³gica, 2018, 57, 1580-1585.	0.8	8
116	Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.. Journal of Clinical Oncology, 2018, 36, 4500-4500.	0.8	78
117	Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2018, 36, 4511-4511.	0.8	12
118	Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Exploratory pharmacogenomic analysis.. Journal of Clinical Oncology, 2018, 36, 576-576.	0.8	1
119	IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC). Journal of Clinical Oncology, 2018, 36, 578-578.	0.8	164
120	Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology, 2018, 36, 581-581.	0.8	15
121	Real world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology, 2018, 36, 615-615.	0.8	2
122	Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy.. Journal of Clinical Oncology, 2018, 36, 667-667.	0.8	0
123	Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology, 2017, 71, 204-209.	0.9	65
124	Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal CellÂCarcinoma. Clinical Genitourinary Cancer, 2017, 15, 403-410.e2.	0.9	14
125	CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. European Urology, 2017, 72, 962-971.	0.9	199
126	Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. European Urology, 2017, 72, 368-376.	0.9	209

#	Article	IF	Citations
127	Characterizing the outcomes of metastatic papillary renal cell carcinoma. Cancer Medicine, 2017, 6, 902-909.	1.3	37
128	Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma. European Journal of Cancer, 2017, 81, 9-16.	1.3	13
129	On-treatment biomarkers in metastatic renal cell carcinoma: towards individualization of prognosis?. Expert Review of Anticancer Therapy, 2017, 17, 97-99.	1.1	3
130	Dynamic Contrast-Enhanced Computed Tomographyâ€"Derived Blood Volume and Blood Flow Correlate With Patient Outcome in Metastatic Renal Cell Carcinoma. Investigative Radiology, 2017, 52, 103-110.	3.5	15
131	Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. European Urology, 2017, 71, 970-978.	0.9	12
132	Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). Kidney Cancer, 2017, 1, 41-47.	0.2	13
133	Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. Journal of Clinical Oncology, 2017, 35, 3916-3923.	0.8	316
134	Synchronous vs metachronous metastatic disease: Impact of time to metastasis on outcome in metastatic renal cell carcinoma patients treated with targeted therapy. Annals of Oncology, 2017, 28, v311-v312.	0.6	0
135	Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT).. Journal of Clinical Oncology, 2017, 35, 4507-4507.	0.8	28
136	Pazopanib exposure-response assessment as adjuvant therapy for patients with localized or locally advanced renal cell carcinoma (RCC) following nephrectomy.. Journal of Clinical Oncology, 2017, 35, 4564-4564.	0.8	7
137	Fourth-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology, 2017, 35, 498-498.	0.8	5
138	Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in patients with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2017, 35, 517-517.	0.8	2
139	Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2017, 35, 4570-4570.	0.8	1
140	Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).. Journal of Clinical Oncology, 2017, 35, e16065-e16065.	0.8	0
141	Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2017, 35, 4578-4578.	0.8	1
142	The database of the Danish Renal Cancer Group. Clinical Epidemiology, 2016, Volume 8, 725-729.	1.5	9
143	The Advent of Psycho-oncology in Metastatic Renal Cell Carcinoma. European Urology Focus, 2016, 2, 650-651.	1.6	0
144	Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. New England Journal of Medicine, 2016, 375, 2246-2254.	13.9	640

#	Article	IF	Citations
145	First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Journal of Cancer, 2016, 65, 102-108.	1.3	60
146	genitourinary tumours, non prostate Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC). Annals of Oncology, 2016, 27, vi565.	0.6	2
147	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2016, 17, 917-927.	5.1	789
148	Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. European Urology, 2016, 70, 358-364.	0.9	133
149	A five-factor biomarker profile obtained week 4â€“12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2. Acta OncolÃ³gica, 2016, 55, 341-348.	0.8	15
150	Sunitinibâ€induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma. BJU International, 2016, 117, 110-117.	1.3	47
151	Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2016, 34, 4506-4506.	0.8	1
152	Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study.. Journal of Clinical Oncology, 2016, 34, 4509-4509.	0.8	11
153	A randomized phase II trial of interleukin-2/interferon-Î± plus bevacizumab versus interleukin-2/interferon-Î± in metastatic renal cell carcinoma (mRCC): Results from the Danish Renal Cancer Group (DARENCA) study 1.. Journal of Clinical Oncology, 2016, 34, 4563-4563.	0.8	5
154	Outcomes of metastatic chromophobe renal cell carcinoma (chrRCC) in the targeted therapy era: Results from the International Metastatic Renal Cell Cancer Database Consortium.. Journal of Clinical Oncology, 2016, 34, 4570-4570.	0.8	1
155	CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2016, 34, 498-498.	0.8	21
156	Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2016, 34, 499-499.	0.8	10
157	First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology, 2016, 34, 544-544.	0.8	1
158	The impact of active smoking on survival outcome in metastatic renal cell carcinoma patients treated with targeted therapy.. Journal of Clinical Oncology, 2016, 34, 552-552.	0.8	1
159	Change in International mRCC Database Consortium (IMDC) prognostic category and implications for efficacy of second-line targeted therapy.. Journal of Clinical Oncology, 2016, 34, 534-534.	0.8	0
160	Discontinuing VEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2016, 34, 503-503.	0.8	1
161	Characterizing the outcomes of metastatic papillary renal cell carcinoma (papRCC).. Journal of Clinical Oncology, 2016, 34, 4554-4554.	0.8	0
162	First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell carcinoma database consortium (IMDC).. Journal of Clinical Oncology, 2016, 34, 4510-4510.	0.8	0

#	Article	IF	Citations
163	Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. Clinical Genitourinary Cancer, 2015, 13, e79-e85.	0.9	78
164	The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncology, The, 2015, 16, 293-300.	5.1	299
165	Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2015, 373, 1814-1823.	13.9	1,004
166	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2015, 373, 1803-1813.	13.9	4,889
167	Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. British Journal of Cancer, 2015, 113, 1571-1580.	2.9	88
168	Health Economic Changes as a Result of Implementation of Targeted Therapy for Metastatic Renal Cell Carcinoma: National Results from DARENCA Study 2. European Urology, 2015, 68, 516-522.	0.9	10
169	Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. European Urology, 2015, 68, 506-515.	0.9	41
170	Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database Consortium. Clinical Genitourinary Cancer, 2015, 13, 150-155.	0.9	10
171	Third-line therapy in metastatic renal cell carcinoma: Results from the International mRCC Database Consortium.. Journal of Clinical Oncology, 2015, 33, 430-430.	0.8	3
172	Third-line therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology, 2015, 33, e15578-e15578.	0.8	1
173	Characteristics of metastatic renal cell carcinoma (mRCC) patients treated with delayed targeted therapy: Results from the International mRCC Consortium (IMDC).. Journal of Clinical Oncology, 2015, 33, 4558-4558.	0.8	0
174	Tumor-Associated Neutrophils as a New Prognostic Factor in Cancer: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e98259.	1.1	279
175	Hypertension, Neutropenia, Thrombocytopenia, Normal Sodium and Ldh Within the First 12 Weeks of Treatment As Independent Biomarkers of Outcome in Metastatic Renal Cell Carcinoma (Mrcc). Annals of Oncology, 2014, 25, iv284.	0.6	0
176	First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. British Journal of Cancer, 2014, 110, 1917-1922.	2.9	64
177	Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Annals of Oncology, 2014, 25, 149-154.	0.6	121
178	Dynamic Contrast-Enhanced Computed Tomography as a Potential Biomarker in Patients With Metastatic Renal Cell Carcinoma. Investigative Radiology, 2014, 49, 601-607.	3.5	21
179	Efficacy of Targeted Therapy for Metastatic Renal Cell Carcinoma in the Elderly Patient Population. Clinical Genitourinary Cancer, 2014, 12, 354-358.	0.9	26
180	Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: Results from the Danish Renal Cancer Group (DARENCA) study-2. European Journal of Cancer, 2014, 50, 553-562.	1.3	69

#	Article	IF	Citations
181	Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy. European Urology, 2014, 65, 577-584.	0.9	207
182	Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology, 2014, 66, 704-710.	0.9	382
183	First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium. Clinical Genitourinary Cancer, 2014, 12, 335-340.	0.9	9
184	The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. European Urology, 2014, 65, 723-730.	0.9	69
185	A Population-Based Overview of Sequences of Targeted Therapy in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2014, 12, e127-e131.	0.9	25
186	Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. European Urology, 2014, 65, 1086-1092.	0.9	71
187	Strong Prognostic Value of Tumor-infiltrating Neutrophils and Lymphocytes Assessed by Automated Digital Image Analysis in Early Stage Cervical Cancer: A Comparator Study with Observer-assisted Stereological Assessments. The Journal of Oncopathology, 2014, 2, 1-9.	0.1	3
188	Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. Journal of Clinical Oncology, 2014, 32, 396-396.	0.8	9
189	The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT).. Journal of Clinical Oncology, 2014, 32, 398-398.	0.8	7
190	The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Targeted Oncology, 2013, 8, 203-209.	1.7	47
191	Metastatic nonâ€“clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer, 2013, 119, 2999-3006.	2.0	189
192	Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. Journal of Translational Medicine, 2013, 11, 189.	1.8	25
193	External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncology, The, 2013, 14, 141-148.	5.1	808
194	Combination of Zoledronic Acid and Targeted Therapy Is Active But May Induce Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Carcinoma. Journal of Oral and Maxillofacial Surgery, 2013, 71, 1532-1540.	0.5	57
195	Immunomonitoring and prognostic relevance of neutrophils in clinical trials. Seminars in Cancer Biology, 2013, 23, 200-207.	4.3	250
196	Tumor-associated neutrophils and macrophages in non-small cell lung cancer: No immediate impact on patient outcome. Lung Cancer, 2013, 81, 130-137.	0.9	101
197	Carbon anhydrase IX specific immune responses in patients with metastatic renal cell carcinoma potentially cured by interleukin-2 based immunotherapy. Immunopharmacology and Immunotoxicology, 2013, 35, 487-496.	1.1	5
198	Tumour-associated CD66b+ neutrophil count is an independent prognostic factor for recurrence in localised cervical cancer. British Journal of Cancer, 2013, 108, 2116-2122.	2.9	95

#	Article	IF	Citations
199	Outcome of metastatic sarcomatoid renal cell carcinoma (sRCC): Results from the International mRCC Database Consortium.. Journal of Clinical Oncology, 2013, 31, 4565-4565.	0.8	4
200	First-, second-, third-line therapy for metastatic renal cell carcinoma (mRCC): Benchmarks for trials design from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology, 2013, 31, 4586-4586.	0.8	1
201	Impact of bone and liver metastases (BM, LM) in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs): Results from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology, 2013, 31, 394-394.	0.8	2
202	Metastatic nonâ€“clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Applying the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model to predict outcomes.. Journal of Clinical Oncology, 2013, 31, 396-396.	0.8	1
203	First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An updated analysis from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology, 2013, 31, e15518-e15518.	0.8	0
204	Tumor-associated CD66b+ neutrophil and CD8+ lymphocyte densities as independent prognostic factors for recurrence in localized cervical cancer: Automated digital image analysis and observer-assisted stereological assessments.. Journal of Clinical Oncology, 2013, 31, 5532-5532.	0.8	0
205	Treatment response and survival outcome of patients with late relapse (LR) from renal cell carcinoma (RCC) in the era of targeted therapy.. Journal of Clinical Oncology, 2013, 31, 4578-4578.	0.8	0
206	Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Annals of Oncology, 2012, 23, 1549-1555.	0.6	121
207	Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncology, The, 2012, 13, 927-935.	5.1	112
208	Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer, 2012, 118, 2476-2485.	2.0	219
209	Comparative Assessment of Sunitinib-Associated Adverse Events (AES) as Potential Biomarkers of Efficacy in Metastatic Renal Cell Carcinoma (MRCC). Annals of Oncology, 2012, 23, ix259.	0.6	7
210	Blood and tumor inflammation markers in non-small cell lung cancer (NSCLC): Blood leukocytosis as an independent risk factor in early stage.. Journal of Clinical Oncology, 2012, 30, e21110-e21110.	0.8	0
211	An in-depth multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility criteria for clinical trials.. Journal of Clinical Oncology, 2012, 30, 4536-4536.	0.8	4
212	Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma (mRCC) treated with targeted therapy: Results from the International mRCC Database Consortium.. Journal of Clinical Oncology, 2012, 30, 4538-4538.	0.8	0
213	1141 POSTER Neutropenia and Thrombocytopenia During Treatment as Biomarkers of Sunitinib Efficacy in Patients With Metastatic Renal Cell Carcinoma (mRCC). European Journal of Cancer, 2011, 47, S136.	1.3	13
214	Wildtype p53-specific Antibody and T-Cell Responses in Cancer Patients. Journal of Immunotherapy, 2011, 34, 629-640.	1.2	10
215	Progressionâ€free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer, 2011, 117, 2637-2642.	2.0	74
216	Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma. British Journal of Cancer, 2010, 102, 867-872.	2.9	89

#	Article	IF	Citations
217	Presence of Intratumoral Neutrophils Is an Independent Prognostic Factor in Localized Renal Cell Carcinoma. Journal of Clinical Oncology, 2009, 27, 4709-4717.	0.8	385
218	Increased Intratumoral FOXP3-positive Regulatory Immune Cells during Interleukin-2 Treatment in Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2009, 15, 1052-1058.	3.2	80
219	Immunohistochemical expression of carbonic anhydrase IX assessed over time and during treatment in renal cell carcinoma. BJU International, 2008, 101, 41-44.	1.3	15
220	Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma. Danish Medical Bulletin, 2007, 54, 249-65.	0.3	8
221	Impact of Immune Parameters on Long-Term Survival in Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2006, 24, 1997-2005.	0.8	271
222	Monocytes and neutrophils as â€˜bad guysâ€™ for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma â€“ results from a randomised phase II trial. British Journal of Cancer, 2006, 94, 218-226.	2.9	67
223	Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma. British Journal of Cancer, 2005, 93, 757-762.	2.9	24
224	Fas Ligand Expression in Metastatic Renal Cell Carcinoma During Interleukin-2 Based Immunotherapy. Clinical Cancer Research, 2004, 10, 7911-7916.	3.2	11
225	In vivo assessment of the antiproliferative properties of interferon-alpha during immunotherapy: Ki-67 (MIB-1) in patients with metastatic renal cell carcinoma. British Journal of Cancer, 2004, 90, 626-631.	2.9	12
226	Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy, 2004, 53, 729-739.	2.0	45
227	Immune response in blood and tumour tissue in patients with metastatic malignant melanoma treated with IL-2, IFN alpha and histamine dihydrochloride. Anticancer Research, 2003, 23, 537-42.	0.5	10
228	Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival. British Journal of Cancer, 2002, 87, 194-201.	2.9	50
229	Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-Î± in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II study. Annals of Oncology, 2002, 13, 441-449.	0.6	20
230	Expression and function of LFA-1 on A-NK and T-LAK cells: role in tumor target killing and migration into tumor tissue. Natural Immunity, 1996, 15, 134-46.	0.2	6